We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




European Nonprofit to Focus on Personalized Medicine and Diagnostics

By LabMedica International staff writers
Posted on 09 Nov 2009
A nonprofit launched in Europe will focus on promoting and harmonizing personalized medicine and implementing "high value" diagnostics across the continent.

The European Personalized Medicine Diagnostics Association (EPEMED; Nantes, France), a membership association formed in August 2009 as a not-for-profit organization, will provide a platform for harmonization in the development and implementation of value-based diagnostics across Europe, to make personalized medicine a reality. More...
Personalized Medicine refers to the use of a person's clinical, genetic, genomic, and environmental information to select more precisely and accurately treatment for each individual patient. Its aims are to improve care and lower costs.

The central goals of EPEMED are to move personalized medicine forward throughout Europe through targeted education, idea sharing, and business models. The group plans to create joint programs with other international personalized medicine organizations, and to offer opinions on policies related to the field.

EPEMED appointed experts in the field of personalized medicine and molecular diagnostics as its founding board of directors. They include executives from Ipsogen (Marseilles, France), Genzyme Genetics (Cambridge, MA, USA), the Personalized Medicine Coalition (Washington, DC, USA), Theranostics (Rockville, MD, USA), and Novartis Molecular Diagnostics (East Hanover, NJ, USA), as well as from academic and institutional researchers, other businesses, and patient advocacy groups.

"The next few years will see deep changes in medical care due to the development of breakthrough innovations in the field of molecular diagnostics that will help clinicians in better treating their patients," Alain Huriez, founder and chairman of EPEMED, said in a statement. "It is our responsibility to make sure that these innovations will be made available to European patients and as a result, to make Europe an attractive place for innovations, financial and industrial investments in the area of personalized medicine diagnostics."

Related Links:

European Personalised Medicine Diagnostics Association
Ipsogen
Genzyme Genetics
Personalized Medicine Coalition
Theranostics
Novartis Molecular Diagnostics


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
PSA Assay
CanAg PSA EIA
New
Gold Member
Pipette Management Software
VIALINK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.